Peregrine Capital Management LLC lowered its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 9.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 96,386 shares of the company’s stock after selling 10,453 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.22% of Axsome Therapeutics worth $7,434,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its holdings in Axsome Therapeutics by 582.0% during the first quarter. Captrust Financial Advisors now owns 757 shares of the company’s stock worth $31,000 after purchasing an additional 646 shares in the last quarter. Quent Capital LLC acquired a new stake in Axsome Therapeutics during the third quarter worth approximately $54,000. Great West Life Assurance Co. Can acquired a new stake in Axsome Therapeutics during the third quarter worth approximately $69,000. Columbia Asset Management acquired a new stake in Axsome Therapeutics during the third quarter worth approximately $89,000. Finally, Tortoise Investment Management LLC raised its holdings in Axsome Therapeutics by 63.0% during the third quarter. Tortoise Investment Management LLC now owns 2,135 shares of the company’s stock worth $95,000 after purchasing an additional 825 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Axsome Therapeutics in a report on Thursday. They set a “sell” rating on the stock. BTIG Research raised their target price on shares of Axsome Therapeutics from $62.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, December 23rd. Mizuho restated a “buy” rating and set a $84.00 target price on shares of Axsome Therapeutics in a research report on Monday, March 13th. Morgan Stanley lowered their target price on shares of Axsome Therapeutics from $86.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 28th. Finally, SVB Leerink raised their target price on shares of Axsome Therapeutics from $65.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 29th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $104.64.
Axsome Therapeutics Stock Performance
Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last issued its earnings results on Monday, February 27th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.10). The business had revenue of $24.37 million for the quarter, compared to the consensus estimate of $21.51 million. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -4.52 EPS for the current year.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.